Which of the following statements regarding ticlopidine is TRUE ?
**Core Concept**
Ticlopidine is an antiplatelet medication that inhibits platelet activation and aggregation by irreversibly blocking the P2Y12 receptor on platelet membranes. This receptor plays a crucial role in platelet activation and the subsequent formation of thrombi.
**Why the Correct Answer is Right**
Ticlopidine works by forming a stable covalent bond with the cysteine residue in the P2Y12 receptor, thereby preventing ADP from binding and activating the receptor. This leads to a decrease in platelet aggregation and thrombus formation. The mechanism of action of ticlopidine is similar to that of clopidogrel, another widely used P2Y12 inhibitor.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because ticlopidine does not directly inhibit the COX-1 enzyme, which is involved in the production of thromboxane A2 and platelet aggregation. Instead, it targets the P2Y12 receptor.
**Option B:** This option is incorrect because ticlopidine is not a direct thrombin inhibitor. It works by inhibiting platelet activation and aggregation, rather than directly inhibiting the thrombin enzyme.
**Option C:** This option is incorrect because ticlopidine is not a direct inhibitor of the glycoprotein IIb/IIIa receptor. It works by inhibiting the P2Y12 receptor, which is a different target.
**Clinical Pearl / High-Yield Fact**
Ticlopidine was one of the first P2Y12 inhibitors to be used clinically, but it has largely been replaced by clopidogrel due to its side effect profile, including a risk of neutropenia and thrombotic thrombocytopenic purpura (TTP).
**Correct Answer: D. Ticlopidine works by irreversibly blocking the P2Y12 receptor on platelet membranes, thereby inhibiting platelet activation and aggregation.**